The burden of prostate cancer is high globally and
especially among men of African descent. Serum prostate
specific antigen(PSA) has long been used for
diagnosis,however,its low specificity and indiscriminate use
has led to unnecessary biopsies,over-diagnosis and over
treatment of apparently indolent tumours.This weakness of
PSA as a biomarker for cancer prostate has necessitated the
search and identification of an alternative to it.
To compare the sensitivity, specificity, positive
predictive value, and negative predictive value of serum
Microseminoprotein-beta(MSMB) with serum total
prostate specific antigen (tPSA) in the diagnosis of prostate
cancer in African men.
This is a 12-month prospective study of patients aged
50 years and above with lower urinary tract symptoms
(LUTS), PSA greater than 4ng/ml and/or abnormal digital
rectal examination, leading to the suspicion of prostate
cancer. Patients with a histological diagnosis of prostate
cancer formed the study group while those with negative
biopsy/benign prostatic hyperplasia on histology served as
the control group.All had detailed history and focused
examination with serum levels of Microseminoproteinbeta(MSMB) and total PSA (tPSA) determined using
Enzyme-linked immunosorbent assay methods. Data were
analyzed using SPSS version 20.0 for windows.
The mean age of patients with prostate cancer and
those with benign prostatic hyperplasia (BPH)/negative
biopsy was 67.40 ± 9.08 and 65.43 ± 9.68 years, with an age
range of 50-91 and 50-89 years, respectively. Compared to
MSMB, tPSA had a higher sensitivity (82.5 vs 57.5%),
specificity (77.5 vs 30.0%), PPV (78.6 vs 45.1), NPV (81.6 vs
41.4%) and diagnostic accuracy (80.6 vs 43.8%).
Serum total PSA had a higher validity than serum
MSMB in diagnosing prostate cancer. Hence, tPSA remains
a relevant serum tumour biomarker in diagnosing prostate
cancer in our urological practice.
Keywords : Prostate Cancer, Microseminoprotein-Beta, Total Prostate-Specific Antigen, Sensitivity, Specificity, Diagnostic Accuracy.